BCLXL-PROTAC, a precision-designed protein degrader, successfully triggered apoptosis in senescent lung cells from COPD patients while sparing healthy cells. The compound reduced key senescence markers including p21CIP1, p16INK4a, and senescence-associated β-galactosidase, while activating caspase 3 death pathways. Crucially, treated tissue samples showed increased Ki67 proliferation markers, indicating cellular renewal. This selective clearance represents a significant advancement in senolytic drug development. Traditional senolytics often lack precision, affecting both damaged and healthy cells. The PROTAC approach—which hijacks cellular machinery to degrade specific proteins—offers unprecedented selectivity. For lung health and longevity, this matters enormously. COPD affects 400 million people globally, with cellular senescence driving progressive lung destruction. The compound's effectiveness in actual patient lung tissue slices, not just isolated cells, suggests real therapeutic potential. However, this remains early-stage research requiring extensive safety testing. The broader implication extends beyond COPD: if BCLXL-PROTAC can rejuvenate lung tissue by precisely eliminating senescent cells, similar approaches might address cellular aging across multiple organ systems, potentially extending healthspan.